Advertisement
UK markets closed

  • FTSE 100

    8,146.86
    -16.81 (-0.21%)
     

  • FTSE 250

    20,120.36
    -75.54 (-0.37%)
     

  • AIM

    776.04
    -4.39 (-0.56%)
     

  • GBP/EUR

    1.1848
    -0.0031 (-0.26%)
     

  • GBP/USD

    1.2688
    -0.0072 (-0.57%)
     

  • Bitcoin GBP

    52,427.43
    +314.85 (+0.60%)
     

  • CMC Crypto 200

    1,382.92
    -34.95 (-2.47%)
     

  • S&P 500

    5,431.60
    -2.14 (-0.04%)
     

  • DOW

    38,589.16
    -57.94 (-0.15%)
     

  • CRUDE OIL

    78.49
    +0.04 (+0.05%)
     

  • GOLD FUTURES

    2,348.40
    -0.70 (-0.03%)
     

  • NIKKEI 225

    38,814.56
    +94.06 (+0.24%)
     

  • HANG SENG

    17,941.78
    -170.82 (-0.94%)
     

  • DAX

    18,002.02
    -263.68 (-1.44%)
     

  • CAC 40

    7,503.27
    -204.75 (-2.66%)
     

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

PR Newswire
·1-min read

CAMBRIDGE, Mass., May 23, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 5 at 9:00 a.m. ET.

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)

The Jefferies Global Healthcare Conference will take place in New York, NY on June 4-6, 2024.

A webcast of the presentation can be accessed through the "Investors" section of Akebia's website at https://ir.akebia.com for 30 days following the conference.

ADVERTISEMENT

About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-302153546.html

SOURCE Akebia Therapeutics, Inc.